News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
198,169 Results
Type
Article (19679)
Company Profile (105)
Press Release (178385)
Section
Business (63979)
Career Advice (820)
Deals (9065)
Drug Delivery (75)
Drug Development (18879)
Employer Resources (138)
FDA (3325)
Job Trends (6004)
News (95383)
Policy (7059)
Tag
Academia (1492)
Alliances (17372)
Alzheimer's disease (524)
Antibody-drug conjugate (ADC) (57)
Approvals (3317)
Artificial intelligence (112)
Best Places to Work (4904)
Biotechnology (64)
Breast cancer (80)
Cancer (552)
Career advice (720)
CAR-T (53)
Cell therapy (139)
Clinical research (14259)
Collaboration (323)
Compensation (62)
COVID-19 (984)
C-suite (92)
Data (509)
Diabetes (60)
Diagnostics (2335)
Earnings (14530)
Employer resources (118)
Events (29419)
Executive appointments (317)
FDA (3575)
Funding (290)
Gene therapy (92)
GLP-1 (299)
Government (1320)
Healthcare (4951)
Infectious disease (1038)
Inflammatory bowel disease (54)
Interviews (115)
IPO (3635)
Job creations (1316)
Job search strategy (634)
Layoffs (154)
Legal (1185)
Lung cancer (87)
Manufacturing (108)
Medical device (2590)
Medtech (2594)
Mergers & acquisitions (5613)
Metabolic disorders (188)
Neuroscience (680)
NextGen: Class of 2025 (2092)
Non-profit (1676)
Northern California (696)
Obesity (119)
Opinion (101)
People (26984)
Phase I (4218)
Phase II (5917)
Phase III (5665)
Pipeline (212)
Postmarket research (562)
Preclinical (2382)
Press Release (61)
Radiopharmaceuticals (63)
Rare diseases (104)
Real estate (2518)
Regulatory (5051)
Research institute (1259)
Resumes & cover letters (106)
Series A (59)
Southern California (470)
Startups (1995)
United States (5835)
Vaccines (189)
Weight loss (89)
Date
Today (24)
Last 7 days (242)
Last 30 days (836)
Last 365 days (11072)
2025 (1761)
2024 (11511)
2023 (13055)
2022 (15628)
2021 (17774)
2020 (16396)
2019 (15052)
2018 (10872)
2017 (10379)
2016 (10251)
2015 (10966)
2014 (8010)
2013 (6932)
2012 (7359)
2011 (7533)
2010 (7020)
Location
Africa (329)
Arizona (60)
Asia (11239)
Australia (1963)
California (1450)
Canada (539)
China (122)
Colorado (81)
Connecticut (68)
Delaware (64)
Europe (28958)
Florida (214)
Illinois (120)
Indiana (127)
Japan (56)
Maryland (174)
Massachusetts (1199)
Michigan (84)
Minnesota (104)
New Jersey (466)
New York (562)
North Carolina (296)
Northern California (696)
Ohio (58)
Pennsylvania (232)
South America (398)
Southern California (470)
Texas (185)
Washington State (116)
198,169 Results for "gilead sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gilead Sciences to Present at Upcoming March 2025 Investor Conferences
February 19, 2025
·
1 min read
Infectious disease
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
February 12, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
January 13, 2025
·
2 min read
·
Tristan Manalac
Pipeline
JPM25 Day 3: AbbVie, Gilead, GSK and Dyne
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for sustainable success in 2025.
January 16, 2025
·
3 min read
·
Tristan Manalac
Deals
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.
January 22, 2025
·
5 min read
·
Annalee Armstrong
Press Releases
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
·
19 min read
Press Releases
Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend
February 12, 2025
·
1 min read
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Antibody-drug conjugate
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder cancer and its late-stage fail in NSCLC.
December 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences to Present at Upcoming January 2025 Investor Conference
December 23, 2024
·
1 min read
1 of 19,817
Next
